Recurrent Melanoma Completed Phase 2 Trials for DB00041 (Aldesleukin)

IndicationStatusPhase
DBCOND0028662 (Recurrent Melanoma)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00005949Vaccine Plus Interleukin-2 in Treating Patients With Advanced MelanomaTreatment